These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 589308

  • 1. Acute leukaemia after busulphan.
    Stott H, Fox W, Girling DJ, Stephens RJ, Galton DA.
    Br Med J; 1977 Dec 10; 2(6101):1513-7. PubMed ID: 589308
    [Abstract] [Full Text] [Related]

  • 2. 5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus.
    Stott H, Stephens RJ, Fox W, Roy DC.
    Br J Cancer; 1976 Aug 10; 34(2):167-73. PubMed ID: 786362
    [Abstract] [Full Text] [Related]

  • 3. Study of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus. Report by a Medical Research Council Working Party.
    Medical Research Council Working Party.
    Br Med J; 1971 May 22; 2(5759):421-8. PubMed ID: 4930389
    [Abstract] [Full Text] [Related]

  • 4. An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung.
    Stott H, Stephens R, Fox W, Simon G, Roy DC.
    Thorax; 1976 Jun 22; 31(3):265-70. PubMed ID: 781905
    [Abstract] [Full Text] [Related]

  • 5. Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia.
    Bowcock SJ, Galton DA, Goldman JM.
    Eur J Haematol; 1989 May 22; 42(5):496-7. PubMed ID: 2567249
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma.
    Girling DJ, Stott H, Stephens RJ, Fox W.
    Br J Cancer; 1985 Dec 22; 52(6):867-73. PubMed ID: 3907687
    [Abstract] [Full Text] [Related]

  • 8. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children.
    Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CJ, Barnes R.
    Bone Marrow Transplant; 1986 Dec 22; 1(2):193-200. PubMed ID: 3332132
    [Abstract] [Full Text] [Related]

  • 9. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis.
    Nagler A, Savani BN, Labopin M, Polge E, Passweg J, Finke J, Kyrcz-Krzemien S, Volin L, Anagnostopoulos A, Aljurf M, Beelen DW, Vigouroux S, Milpied N, Suarez F, Mohty M.
    Lancet Haematol; 2015 Sep 22; 2(9):e384-92. PubMed ID: 26685771
    [Abstract] [Full Text] [Related]

  • 10. Chronic myeloid leukaemia and a myasthenic syndrome.
    Wohl MA, Wood JK.
    Acta Haematol; 1979 Sep 22; 62(4):214-8. PubMed ID: 119414
    [Abstract] [Full Text] [Related]

  • 11. Remission induction in chronic granulocytic leukaemia using intermittent high-dose busulphan.
    Douglas ID, Wiltshaw E.
    Br J Haematol; 1978 Sep 22; 40(1):59-64. PubMed ID: 280361
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Portal hypertension in a patient with chronic myeloid leukaemia.
    Foadi MD, Shaw S, Paradinas FJ.
    Postgrad Med J; 1977 May 22; 53(619):267-9. PubMed ID: 267281
    [Abstract] [Full Text] [Related]

  • 15. Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
    Olsson-Strömberg U, Simonsson B, Ahlgren T, Björkholm M, Carlsson K, Gahrton G, Hast R, Löfvenberg E, Linder O, Ljungman P, Malm C, Paul C, Rödjer S, Turesson I, Udén AM, Wahlin A, Killander A, Wadman B, Westin J, Vikrot O, Zettervall O, Oberg G, Swedish CML Study Group.
    Hematol J; 2004 May 22; 5(6):462-6. PubMed ID: 15570285
    [Abstract] [Full Text] [Related]

  • 16. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.
    Haas JF, Kittelmann B, Mehnert WH, Staneczek W, Möhner M, Kaldor JM, Day NE.
    Br J Cancer; 1987 Feb 22; 55(2):213-8. PubMed ID: 3814491
    [Abstract] [Full Text] [Related]

  • 17. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C, Békassy A, Bielenstein M, Abdel-Rehim M, Georén S, Astner L.
    Bone Marrow Transplant; 2000 May 22; 25(9):915-24. PubMed ID: 10800057
    [Abstract] [Full Text] [Related]

  • 18. Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.
    Thomas AE, Patterson J, Prentice HG, Brenner MK, Ganczakowski M, Hancock JF, Pattinson JK, Blacklock HA, Hopewell JP.
    Bone Marrow Transplant; 1987 Apr 22; 1(4):347-55. PubMed ID: 3139113
    [Abstract] [Full Text] [Related]

  • 19. Relationship of the duration of the chronic phase in chronic granulocytic leukaemia to the need for treatment during the first year after diagnosis.
    Wareham NJ, Johnson SA, Goldman JM.
    Cancer Chemother Pharmacol; 1982 Apr 22; 8(2):205-10. PubMed ID: 6955071
    [Abstract] [Full Text] [Related]

  • 20. [The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
    Zhu K, Xu Y, Wu D, Xu X, Huang L.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug 22; 21(8):403-5. PubMed ID: 11877010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.